Zynerba stock soars after getting 'fast track' designation for experimental cannibanoid therapy

The Food and Drug Administration granted Fast Track Designation Monday to Zynerba Pharmaceuticals' lead synthetically produced cannabinoid therapy candidate The designation applies to the Devon's company's new drug candidate Zygel as a potential treatment for behavioral symptoms associated with Fragile X syndrome. The action sent Zynerba's stock price up nearly 10 percent to $12.54 per share in late morning trading. The FDA’s Fast Track program is designed to speed the development of drugs intended…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news